The use of histology image analysis to accurately quantify biomarker levels in oncology research is a key approach used to better understand the in vivo drug response and mechanism of action of new therapies. Whole slide image analysis can help to extract detailed, quantitative data from IHC-stained tumor tissue sections to allow correlation with in vitro data and help make better decisions regarding compound progression and selection of biomarkers for use during clinical testing.
OracleBio recently completed image analysis quantification of a range of IHC biomarkers within xenograft tumour tissue for MISSION Therapeutics (www.missiontherapeutics.com), a biotech based in Cambridge UK who focus on selectively targeting ubiquitin pathways to treat cancer and other diseases.
The study involved testing a lead compound in a multiple myeloma xenograft model with subsequent quantitative analysis of IHC staining to examine the mechanism of action of the drug. Specifically, changes in the target modulation biomarkers Cleaved Caspase-3 (CC3), c-Myc and p53 were quantified within viable tissue of tumour sections following modulation of the ubiquitin pathway.
Data showed that compound treated samples had significantly higher mean % CC3 staining and mean p53 positive nuclei count per mm2 in viable tumour and a significantly lower mean c-Myc positive nuclei index in viable tumour compared to vehicle treated samples.
Click on the image below to view the full presentation
Dr Aaron Cranston, Group Leader at MISSION Therapeutics, commented, “The ability to obtain truly quantitative IHC data from these types of studies has been invaluable in helping our biology teams evaluate potential biomarkers and validate PK-PD relationships for our drug discovery projects.”
A copy of Dr Cranston’s presentation including examples of the IHC analysis performed by OracleBio (slides 29 – 31) can be viewed by clicking on the image above:
For more information on OracleBio’s oncology biomarker image analysis services please visit our website.